Back to Search Start Over

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer

Authors :
Nero, Camilla
Boldrini, Luca
Lenkowicz, Jacopo
Giudice, M. T.
Piermattei, Angelo
Inzani, Frediano
Pasciuto, Tina
Minucci, Angelo
Fagotti, Anna
Zannoni, Gian Franco
Valentini, Vincenzo
Scambia, Giovanni
Nero C.
Boldrini L.
Lenkowicz J.
Piermattei A. (ORCID:0000-0002-6835-1179)
Inzani F.
Pasciuto T. (ORCID:0000-0003-2959-8571)
Minucci A.
Fagotti A. (ORCID:0000-0001-5579-335X)
Zannoni G. (ORCID:0000-0003-1809-129X)
Valentini V. (ORCID:0000-0003-4637-6487)
Scambia G. (ORCID:0000-0003-2758-1063)
Nero, Camilla
Boldrini, Luca
Lenkowicz, Jacopo
Giudice, M. T.
Piermattei, Angelo
Inzani, Frediano
Pasciuto, Tina
Minucci, Angelo
Fagotti, Anna
Zannoni, Gian Franco
Valentini, Vincenzo
Scambia, Giovanni
Nero C.
Boldrini L.
Lenkowicz J.
Piermattei A. (ORCID:0000-0002-6835-1179)
Inzani F.
Pasciuto T. (ORCID:0000-0003-2959-8571)
Minucci A.
Fagotti A. (ORCID:0000-0001-5579-335X)
Zannoni G. (ORCID:0000-0003-1809-129X)
Valentini V. (ORCID:0000-0003-4637-6487)
Scambia G. (ORCID:0000-0003-2758-1063)
Publication Year :
2022

Abstract

BRCA 1/2 genes mutation status can already determine the therapeutic algorithm of high grade serous ovarian cancer patients. Nevertheless, its assessment is not sufficient to identify all patients with genomic instability, since BRCA 1/2 mutations are only the most well-known mechanisms of homologous recombination deficiency (HR-d) pathway, and patients displaying HR-d behave similarly to BRCA mutated patients. HRd assessment can be challenging and is progressively overcoming BRCA testing not only for prognostic information but more importantly for drugs prescriptions. However, HR testing is not already integrated in clinical practice, it is quite expensive and it is not refundable in many countries. Selecting patients who are more likely to benefit from this assessment (BRCA 1/2 WT patients) at an early stage of the diagnostic process, would allow an optimization of genomic profiling resources. In this study, we sought to explore whether somatic BRCA1/2 genes status can be predicted using computational pathology from standard hematoxylin and eosin histology. In detail, we adopted a publicly available, deep-learning-based weakly supervised method that uses attention-based learning to automatically identify sub regions of high diagnostic value to accurately classify the whole slide (CLAM). The same model was also tested for progression free survival (PFS) prediction. The model was tested on a cohort of 664 (training set: n = 464, testing set: n = 132) ovarian cancer patients, of whom 233 (35.1%) had a somatic BRCA 1/2 mutation. An area under the curve of 0.7 and 0.55 was achieved in the training and testing set respectively. The model was then further refined by manually identifying areas of interest in half of the cases. 198 images were used for training (126/72) and 87 images for validation (55/32). The model reached a zero classification error on the training set, but the performance was 0.59 in terms of validation ROC AUC, with a 0.57 validation accuracy. Finally

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1355227368
Document Type :
Electronic Resource